Minimum 3 years’ experience; preference for someone who has worked at multiple companies
Nursing or pharmacy background strongly preferred
Needs to have experience with the full case processing workflow (mailbox experience/assessing & triaging cases, data entry experience, quality check/review experience, follow up experience as well as submissions experience)
Argus database experience is an absolute must; experience with reports and listings in Argus, as well as experience coding AE and medication within Argus would be nice to have
Candidate would need to have a strong attention to detail, good communication skills, and ability to assess and think critically
January 5, 2018 – Drug Safety Specialist – p b Overview: /b /p ul li The Drug Safety Specialist may be responsible for supporting a number of clinical and postmarketing safety activities,
December 6, 2017 – Drug Safety Specialist – p b Responsibilities or Duties: /b /p ul li Management of individual case study reports (ICSRs). /li li Perform quality control activities to
November 20, 2017 – Pharmacovigilance Drug Safety Specialist – p b Position Description: /b /p ul li Responsible for overseeing all aspects of adverse event case processing and reporting for assigned
August 3, 2017 – Drug Safety Specialist – p b JOB DESCRIPTION: /b /p ul li Healthcare professionals (RN) are highly preferred. Experience and capability to deal with high volume of work
The U.S. Food and Drug Administration today approved Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.
http://www.fda.gov/ || http://www.KatalystHLS.com
Did you know that some drugs affect men and women differently? For instance, women are often prescribed only half the dose that men take of the sleep medication Ambien. Race and ethnicity also make a difference. One type of drug commonly used to treat high blood pressure, ACE inhibitors, has been shown to be less effective in African American patients than in white patients. FDA’s Drug Trials Snapshots Summary Report provides a yearly average of the diversity of participants in the clinical trials for novel drugs approved in 2015 and 2016.